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The term “nanomedicine” is somewhat of a paradox. 
Although “nano” implies something very small, nano-
medicines tend to be much larger than most medicines 
traditionally used in pharmacotherapy. The consequence 
of their larger size is that they are often mistaken by the 
immune system as pathogenic virus, an error that often 
sets off a defense reaction to eliminate the benevolent 
“intruder”. This unwarranted defense reaction may result 
not only in the loss of the medicine’s beneficial effect, but 
also in adverse effects on the patient.
The immune reaction against intravenously applied 
nanomedicines may involve a rapid inflammatory-like 
hypersensitivity reaction, also known as infusion reaction, 
and/or a slow specific response manifested in antibody for-
mation against the drug. The latter “immunogenicity” may 
prevent the drug from carrying out its specific and repro-
ducible therapeutic mission, transforming it into a vaccine. 
Thus, immunogenicity of nanomedicines and biologicals 
with formation of anti-drug antibodies represents a major 
problem in modern pharmacotherapy. Accordingly, the phe-
nomenon has attracted significant attention in the fields of 
experimental and clinical immunology and pharmacology.
In contrast, the issue of infusion hypersensitivity reac-
tions has received much less attention to date. One possi-
ble explanation for the difference is that immunogenicity 
prohibits the use of nanomedicines, while acute hyper-
sensitivity reactions are in most cases preventable and 
manageable, their risk is accepted by the patient and the 
physician. Nevertheless, a small fraction of infusion reac-
tions are not preventable, nor manageable, and cause life 
threatening or even fatal reactions. Due to this, hypersen-
sitivity reactions represent a significant safety concern, 
for which testing in preclinical drug development is listed 
among the most recent regulatory recommendations.
It has been increasingly recognized over the past 
20  years that a major cause of acute infusion reactions 
to liposome- and micelle-based nanomedicines is their 
ability to activate the complement (C) system, which is the 
humoral arm of nonspecific immunity. This phenomenon 
was named C activation-related pseudoallergy or CARPA, a 
term that highlights the mechanism of the reaction. CARPA 
has been the subject of numerous studies and reviews to 
date, evolving into the broader claim that it is a manifes-
tation of the commonly known “stress” phenomenon, 
wherein the body responds to external and internal noxious 
effects with a standard pattern of physiological changes. In 
the case of CARPA the noxious agents are nanoparticulate 
drugs mimicking viruses, the reaction proceeds via the 
anaphylatoxin-mast cell/macrophage axis rather than the 
hypothalamo-pituitary-adrenal one, and the effectors are 
allergy mediators rather than steroid hormones.
As a reflection of growing awareness towards CARPA, 
the current and the 2015 July issue of the European Journal 
of Nanomedicine presents a series of reviews and research 
papers on CARPA, providing an unprecedented spectrum 
of old and new information on the subject. The topics 
addressed in the two issues include a historic account of 
how the concept developed from a problem in liposome 
research to the daring claim that CARPA is a universal 
stress reaction that may afflict most or all animals that 
have C in their blood; the types of reactogenic drugs and 
drug carrier nanosystems; the symptoms and mechanism 
of CARPA; the role of PIM cells; in vitro tests and animal 
models, especially pigs and rodents; prediction of CARPA 
in patients and approaches to prevention, as well as 
various other aspects of C activation and function. The 
guest editors of this two-part series strongly hope that the 
compilation of papers on CARPA in these freely accessi-
ble issues of the European Journal of Nanomedicine will 
significantly contribute to greater understanding of this 
relatively neglected subject and to its further research.
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